NYXOAH Shares Hit Record Low of €2.545 Before Closing
On Monday, March 16, 2026, NYXOAH shares continued to show negative signals: the stock hit a new all-time low during the session at €2.545 and fell nearly 4% by late afternoon, amid the imminent release of the 2025 annual results. The stock is priced at €2.70 after closing at €2.81 on Friday, now marking a 75% decline over the year.
Historic Low on the Day of Annual Results Announcement
This Monday, NYXOAH reached a level never seen since its IPO, at €2.545, coinciding with the J0 day of its 2025 annual results, which are scheduled to be published on March 19. The decline of 3.91% in late afternoon, after a more pronounced drop at the start of the session—where the variation reached -6.5% at the time of the signal detection—illustrates the selling pressure exerted on the stock as this accounting deadline approaches. Over the past week, the decline reached 15.49%, and the three-month performance is at -28.76%. This deterioration occurs in a tense market environment: the VIX is at 27.29 points, indicating increased nervousness in the financial markets. The CAC 40, meanwhile, is up 0.51% during the session this same Monday, at 7,951.89 points, highlighting the specific nature of the correction affecting the Belgian biotech.
Technical Analysis Shows Strained Configuration
From a technical analysis perspective, the stock's configuration is particularly tense. The RSI is at 11, an extremely low level indicating persistent and prolonged selling pressure on the stock. The two reference moving averages confirm the fundamental bearish orientation: the MM50 is at €3.88 and the MM200 at €4.97, both significantly above the current price, signaling a stock operating in a severely degraded territory compared to its medium and long-term trends. The previous support at €2.81—corresponding to the last close—was breached during the session with the recording of the new all-time low at €2.545. The current price of €2.70 also moves below the lower boundary of the Bollinger Bands, set at €2.75, confirming the unusual magnitude of the bearish compression. The next significant calendar milestone remains the official release of the 2025 annual results, set for March 19, 2026.
